Article

Lupus Independently Increases Insulin Resistance

Be vigilant for the development of type 2 diabetes in patients with systemic lupus erythematosus.

Keypoints
• Insulin resistance is increased in patients with systemic lupus erythematosus (SLE) compared with control subjects.

• Insulin resistance is related to the damage caused by SLE and may accelerate subclinical atherosclerosis.

• C-peptide levels are up-regulated in patients with lupus.

• There did not appear to be any beneficial effects conferred by anti-rheumatic drugs on insulin resistance.

• Glucocorticoids appear to exert a negative effect on insulin resistance.

Background
SLE is associated with atherosclerosis: patients with lupus have more than twice the risk of cardiovascular events such as stroke and myocardial infarction than the general population.

Sanchez-Perez and colleagues1 in Spain point out that patients with lupus often have several traditional risk factors for cardiovascular disease; however, this fact does not explain their higher risk of premature atherosclerosis independent of those factors. "This finding supports a role for disease-related factors in SLE patients' atherogenesis," state the researchers.

Insulin resistance is a known contributor to cardiovascular disease and in particular atherosclerosis. While previous studies have looked at the metabolic syndrome in patients with lupus as a factor in insulin resistance, few have sought to determine whether SLE itself has an impact on insulin resistance and how that relationship affects subclinical atherosclerosis. Sanchez-Perez and colleagues recently presented their findings in Clinical and Experimental Rheumatology.

Thestudy
This cross-sectional study included 87 patients with SLE and 82 matched control subjects. C-peptide concentrations were measured, ultrasound was used to assess vascular intimal wall thickening, and comorbidities were recorded.

Theresults
• Patients with SLE had higher serum levels of C-peptide than controls (P = .00).

• Patients with SLE also had higher rates of insulin resistance than control subjects (P = .01).

• Following adjustment for steroid intake and traditional insulin resistance factors, the difference between patients with lupus and controls remained statistically significant.

• Prednisone was independently linked to increased insulin resistance.

Implicationsforphysicians
• Be vigilant with regards to insulin resistance and the development of type 2 diabetes in patients with SLE.

• SLE may cause beta cell dysfunction as a disease effect.

• Increased insulin resistance appears to be related to the damage lupus causes over time independent of other traditional risk factors.

• Increased insulin resistance caused by SLE damage may lead to premature atherosclerosis; however, results were not statistically significant in this study.

References:

Sanchez-Perez H, Tejera-Segura B, de Vera-Gonzalez A, et al. Insulin resistance in systemic lupus erythematosus patients: contributing factors and relationship with subclinical atherosclerosis. ClinExpRheumatol. 2017;35:885-892.

Related Videos
Orrin Troum, MD: Accurately Imaging Gout With DECT Scanning
John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research
Philip Conaghan, MBBS, PhD: Investigating NT3 Inhibition for Improving Osteoarthritis
Rheumatologists Recognize the Need to Create Pediatric Enthesitis Scoring Tool
Presence of Diffuse Cutaneous Disease Linked to Worse HRQOL in Systematic Sclerosis
Alexei Grom, MD: Exploring Safer Treatment Options for Refractory Macrophage Activation Syndrome
Jack Arnold, MBBS, clinical research fellow, University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
Laure Gossec, MD, PhD: Informing Physician Treatment Choices for Psoriatic Arthritis
© 2024 MJH Life Sciences

All rights reserved.